Ceapro has extended a partnership underway to carry out a further research project with McMaster University for developing an inhalable immuno-therapeutic/-prophylactic for Covid-19-induced lung fibrosis.
This project is intended to develop therapies for people suffering from Covid-19’s long-term effects.
Go deeper with GlobalData
In August 2019, the parties entered a partnership for new drug delivery system development leveraging the disruptive Pressurized Gas eXpanded Liquid technology (PGX) to streamline drug formulations utilised in areas with unmet medical needs.
The PGX technology has so far shown the potential for purifying and drying yeast beta glucan (YBG) into uniform inhalable particles that are capable of modifying the immune system using a certain mechanism of action.
The new development is aimed at streamlining PGX-YBG delivery to the lung and establishing the anti-fibrotic properties to lower reducing lung fibrosis, both alone and given along with an anti-inflammatory drug used presently for Covid-19.
This assessment in experimental models of lung fibrosis will aid in progressing the technology into a Phase I clinical trial.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCeapro president and CEO Gilles Gagnon said: “Conducting research during a pandemic has been a major challenge, but the McMaster and Ceapro research teams have been relentless despite all the challenges, and I would like to thank them and applaud the innovative work that they have accomplished so far.
“Under the leadership of Drs Kolb, Ask and Hoare, I feel confident that this project will bring benefits to patients while creating value for shareholders.”
A disruptive technology, PGX has various vital advantages compared to standard drying and purification technologies that can be leveraged to process biopolymers into fine-structured, open porous polymer structures, as well as new biocomposites.
PGX is well-fitted for high-molecular-weight, water-soluble biopolymer processing.
It can potentially create ultra-light, highly porous polymer structures continuously, which is not achievable with current technologies.
